Pacific Biosciences of California PACB Estimated Fair Value
Estimated Fair Value at other companies
Other financials
Where this comes from
Reported directly by Pacific Biosciences of California in its filing.
Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest.
The official record: Pacific Biosciences of California’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Pacific Biosciences of California's estimated fair value.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Pacific Biosciences of California's estimated fair value?
- Pacific Biosciences of California (PACB) reported estimated fair value of $275.96M in Q1 2026.
- How has Pacific Biosciences of California's estimated fair value changed year-over-year?
- Pacific Biosciences of California's estimated fair value decreased by 19.6% year-over-year, from $343.11M to $275.96M.
- What is the long-term trend for Pacific Biosciences of California's estimated fair value?
- Over 3 years (2022 to 2025), Pacific Biosciences of California's estimated fair value has grown at a -28.7% compound annual growth rate (CAGR), from $772.32M to $279.51M.